Part Used : เหง้า
Activity : DRUG INTERACTION
Solvent/Active Compound : -
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 60 (M/F=47/13)
N(Treatment) : 30 (M/F=22/8)
Sex : Both sex
Age : 37.3 +/-11.01 years
Route : Oral administration
Dose/Conc.(herb) : 500 mg (two capsules orally), 30 min before morning anti-TB medications
Duration : 4 weeks
Type of interaction : Pharmacokinetics
Interaction with drug : Ethambutol*/Ethambutolum
Dose/Conc.(drug) : 15 mg/kg/day
Remark : This preliminary trial supports the role of ginger in the prevention of antituberculosis (TB)-induced gastrointestinal ADRs including nausea and vomiting. The results weakly support the role of ginger in the prevention of anti-TB induced hepatotoxicity.
Note : Subjects: patients with tuberculosis were divided into ginger group (n=30) or placebo group (n=30, M/F=25/5).
Dose: each capsule containing 250 mg standard powdered rhizome of ginger.
Drug: anti-TB drugs including isonicotinylhydrazide (lNH) (5 mg/kg/day), rifampin (RlF) (10 mg/kg/day), ethambutol (15 mg/kg/day), and pyrazinamide (PZA) (25 mg/kg/day) were administered as once daily dose.
